The beginning of ending hepatitis C virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses

Eui Cheol Shin; Ji Won Han; Wonseok Kang; Takanobu Kato; Seong Jun Kim; Jin Zhong; Seungtaek Kim; Su Hyung Park; Pil Soo Sung; Koichi Watashi; Jun Yong Park; Marc P. Windisch; Jong Won Oh; Takaji Wakita; Kwang Hyub Han; Sung Key Jang

doi:10.3390/v12030302

The beginning of ending hepatitis C virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses

Eui Cheol Shin, Ji Won Han, Wonseok Kang, Takanobu Kato, Seong Jun Kim, Jin Zhong, Seungtaek Kim, Su Hyung Park, Pil Soo Sung, Koichi Watashi, Jun Yong Park, Marc P. Windisch, Jong Won Oh, Takaji Wakita, Kwang Hyub Han, Sung Key Jang

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Hepatitis C virus (HCV) infects ~71 million people worldwide, and 399,000 people die annually due to HCV‐related liver cirrhosis and hepatocellular carcinoma. The use of direct‐acting antivirals results in a sustained virologic response in >95% of patients with chronic HCV infection. However, several issues remain to be solved to eradicate HCV. At the 26th International Symposium on Hepatitis C Virus and Related Viruses (HCV2019) held in Seoul, South Korea, October 5–8, 2019, virologists, immunologists, and clinical scientists discussed these remaining issues and how we can achieve the elimination of HCV.

Original language	English
Article number	302
Journal	Viruses
Volume	12
Issue number	3
DOIs	https://doi.org/10.3390/v12030302
Publication status	Published - 2020

Bibliographical note

Funding Information:
Funding: The authors acknowledge grant support of the National Research Foundation of Korea (NRF) (2017R1A2A1A17069782, E.C.S; 2017M3A9G6068245, S.K; 2019R1I1A1A01059642, P.S.S; 2017M3A9G6068246, M.P.W; and 2014R1A2A1A11052535, M.P.W), the National Research Council of Science & Technology of Korea (CRC‐16‐01‐KRICT, S.J.K), National Natural Science Foundation of China (31670172, J.Z), Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29010205, J.Z), and Japan Agency for Medical Research and Development (AMED) Grants (JP19fk0210036j0002, K.W).

Publisher Copyright:
© 2020 by the authors.

All Science Journal Classification (ASJC) codes

Infectious Diseases
Virology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/v12030302

Cite this

Shin, E. C., Han, J. W., Kang, W., Kato, T., Kim, S. J., Zhong, J., Kim, S., Park, S. H., Sung, P. S., Watashi, K., Park, J. Y., Windisch, M. P., Oh, J. W., Wakita, T., Han, K. H., & Jang, S. K. (2020). The beginning of ending hepatitis C virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses. Viruses, 12(3), Article 302. https://doi.org/10.3390/v12030302

@article{b99bc2db489048eab53888e1680796ae,

title = "The beginning of ending hepatitis C virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses",

abstract = "Hepatitis C virus (HCV) infects ~71 million people worldwide, and 399,000 people die annually due to HCV‐related liver cirrhosis and hepatocellular carcinoma. The use of direct‐acting antivirals results in a sustained virologic response in >95% of patients with chronic HCV infection. However, several issues remain to be solved to eradicate HCV. At the 26th International Symposium on Hepatitis C Virus and Related Viruses (HCV2019) held in Seoul, South Korea, October 5–8, 2019, virologists, immunologists, and clinical scientists discussed these remaining issues and how we can achieve the elimination of HCV.",

author = "Shin, {Eui Cheol} and Han, {Ji Won} and Wonseok Kang and Takanobu Kato and Kim, {Seong Jun} and Jin Zhong and Seungtaek Kim and Park, {Su Hyung} and Sung, {Pil Soo} and Koichi Watashi and Park, {Jun Yong} and Windisch, {Marc P.} and Oh, {Jong Won} and Takaji Wakita and Han, {Kwang Hyub} and Jang, {Sung Key}",

note = "Funding Information: Funding: The authors acknowledge grant support of the National Research Foundation of Korea (NRF) (2017R1A2A1A17069782, E.C.S; 2017M3A9G6068245, S.K; 2019R1I1A1A01059642, P.S.S; 2017M3A9G6068246, M.P.W; and 2014R1A2A1A11052535, M.P.W), the National Research Council of Science & Technology of Korea (CRC‐16‐01‐KRICT, S.J.K), National Natural Science Foundation of China (31670172, J.Z), Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29010205, J.Z), and Japan Agency for Medical Research and Development (AMED) Grants (JP19fk0210036j0002, K.W). Publisher Copyright: {\textcopyright} 2020 by the authors.",

year = "2020",

doi = "10.3390/v12030302",

language = "English",

volume = "12",

journal = "Viruses",

issn = "1999-4915",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

TY - JOUR

T1 - The beginning of ending hepatitis C virus

T2 - A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses

AU - Shin, Eui Cheol

AU - Han, Ji Won

AU - Kang, Wonseok

AU - Kato, Takanobu

AU - Kim, Seong Jun

AU - Zhong, Jin

AU - Kim, Seungtaek

AU - Park, Su Hyung

AU - Sung, Pil Soo

AU - Watashi, Koichi

AU - Park, Jun Yong

AU - Windisch, Marc P.

AU - Oh, Jong Won

AU - Wakita, Takaji

AU - Han, Kwang Hyub

AU - Jang, Sung Key

N1 - Funding Information: Funding: The authors acknowledge grant support of the National Research Foundation of Korea (NRF) (2017R1A2A1A17069782, E.C.S; 2017M3A9G6068245, S.K; 2019R1I1A1A01059642, P.S.S; 2017M3A9G6068246, M.P.W; and 2014R1A2A1A11052535, M.P.W), the National Research Council of Science & Technology of Korea (CRC‐16‐01‐KRICT, S.J.K), National Natural Science Foundation of China (31670172, J.Z), Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29010205, J.Z), and Japan Agency for Medical Research and Development (AMED) Grants (JP19fk0210036j0002, K.W). Publisher Copyright: © 2020 by the authors.

PY - 2020

Y1 - 2020

N2 - Hepatitis C virus (HCV) infects ~71 million people worldwide, and 399,000 people die annually due to HCV‐related liver cirrhosis and hepatocellular carcinoma. The use of direct‐acting antivirals results in a sustained virologic response in >95% of patients with chronic HCV infection. However, several issues remain to be solved to eradicate HCV. At the 26th International Symposium on Hepatitis C Virus and Related Viruses (HCV2019) held in Seoul, South Korea, October 5–8, 2019, virologists, immunologists, and clinical scientists discussed these remaining issues and how we can achieve the elimination of HCV.

AB - Hepatitis C virus (HCV) infects ~71 million people worldwide, and 399,000 people die annually due to HCV‐related liver cirrhosis and hepatocellular carcinoma. The use of direct‐acting antivirals results in a sustained virologic response in >95% of patients with chronic HCV infection. However, several issues remain to be solved to eradicate HCV. At the 26th International Symposium on Hepatitis C Virus and Related Viruses (HCV2019) held in Seoul, South Korea, October 5–8, 2019, virologists, immunologists, and clinical scientists discussed these remaining issues and how we can achieve the elimination of HCV.

UR - http://www.scopus.com/inward/record.url?scp=85081904468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081904468&partnerID=8YFLogxK

U2 - 10.3390/v12030302

DO - 10.3390/v12030302

M3 - Article

C2 - 32168867

AN - SCOPUS:85081904468

SN - 1999-4915

VL - 12

JO - Viruses

JF - Viruses

IS - 3

M1 - 302

ER -

The beginning of ending hepatitis C virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this